{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:11:12Z","timestamp":1770221472031,"version":"3.49.0"},"reference-count":101,"publisher":"Portland Press Ltd.","issue":"21","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"abstract":"<jats:p>Members of the B-cell lymphoma 2 (BCL-2) gene family are attractive targets for cancer therapy as they play a key role in promoting cell survival, a long-since established hallmark of cancer. Clinical utility for selective inhibition of specific anti-apoptotic Bcl-2 family proteins has recently been realized with the Food and Drug Administration (FDA) approval of venetoclax (formerly ABT-199\/GDC-0199) in relapsed chronic lymphocytic leukemia (CLL) with 17p deletion. Despite the impressive monotherapy activity in CLL, such responses have rarely been observed in other B-cell malignancies, and preclinical data suggest that combination therapies will be needed in other indications. Additional selective antagonists of Bcl-2 family members, including Bcl-XL and Mcl-1, are in various stages of preclinical and clinical development and hold the promise of extending clinical utility beyond CLL and overcoming resistance to venetoclax. In addition to direct targeting of Bcl-2 family proteins with BH3 mimetics, combination therapies that aim at down-regulating expression of anti-apoptotic BCL-2 family members or restoring expression of pro-apoptotic BH3 family proteins may provide a means to deepen responses to venetoclax and extend the utility to additional indications. Here, we review recent progress in direct and selective targeting of Bcl-2 family proteins for cancer therapy and the search for rationale combinations.<\/jats:p>","DOI":"10.1042\/bcj20170080","type":"journal-article","created":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:10:38Z","timestamp":1508803838000},"page":"3643-3657","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Therapeutics targeting Bcl-2 in hematological malignancies"],"prefix":"10.1042","volume":"474","author":[{"given":"Astrid","family":"Ruefli-Brasse","sequence":"first","affiliation":[{"name":"Roche, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Reed","sequence":"additional","affiliation":[{"name":"Roche, Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"2021112216423015000_BCJ-2017-0080CC1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd726","article-title":"Apoptosis-based therapies","volume":"1","author":"Reed","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"2021112216423015000_BCJ-2017-0080CC2","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.V89.6.1845","article-title":"Apoptosis and the dilemma of cancer chemotherapy","volume":"89","author":"Hannun","year":"1997","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1126\/science.281.5381.1305","article-title":"Death receptors: signaling and modulation","volume":"281","author":"Ashkenazi","year":"1998","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/cbt.4.2.1508","article-title":"Overview of cell death signaling pathways","volume":"4","author":"Jin","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"2021112216423015000_BCJ-2017-0080CC5","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1074\/jbc.273.6.3388","article-title":"Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex","volume":"273","author":"Medema","year":"1998","journal-title":"J. Biol. Chem."},{"key":"2021112216423015000_BCJ-2017-0080CC6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/emboj\/17.6.1675","article-title":"Two CD95 (APO-1\/Fas) signaling pathways","volume":"17","author":"Scaffidi","year":"1998","journal-title":"EMBO J."},{"key":"2021112216423015000_BCJ-2017-0080CC7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1126\/science.6610211","article-title":"Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation","volume":"224","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"key":"2021112216423015000_BCJ-2017-0080CC10","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1126\/science.281.5381.1322","article-title":"The Bcl-2 protein family: arbiters of cell survival","volume":"281","author":"Adams","year":"1998","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1126\/science.1215568","article-title":"Cancer. Priming cancer cells for death","volume":"334","author":"Reed","year":"2011","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","article-title":"BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents","volume":"12","author":"Deng","year":"2007","journal-title":"Cancer Cell"},{"key":"2021112216423015000_BCJ-2017-0080CC13","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.V90.3.1168","article-title":"BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma","volume":"90","author":"Monni","year":"1997","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC15","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216423015000_BCJ-2017-0080CC16","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216423015000_BCJ-2017-0080CC17","first-page":"1309","article-title":"Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo","volume":"146","author":"Krajewski","year":"1995","journal-title":"Am. J. Pathol."},{"key":"2021112216423015000_BCJ-2017-0080CC18","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC19","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3109\/10428194.2011.569962","article-title":"Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1","volume":"52","author":"Herishanu","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"2021112216423015000_BCJ-2017-0080CC20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V91.1.244","article-title":"Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival","volume":"91","author":"Ghia","year":"1998","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC21","doi-asserted-by":"publisher","first-page":"10872","DOI":"10.1073\/pnas.190210897","article-title":"Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution","volume":"97","author":"Ionov","year":"2000","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112216423015000_BCJ-2017-0080CC22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","article-title":"Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas","volume":"109","author":"Mestre-Escorihuela","year":"2007","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC23","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1182\/blood-2010-05-284968","article-title":"Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition","volume":"116","author":"Bachmann","year":"2010","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1126\/science.274.5292.1531","article-title":"Discovering high-affinity ligands for proteins: SAR by NMR","volume":"274","author":"Shuker","year":"1996","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"2021112216423015000_BCJ-2017-0080CC26","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC27","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/leu.2009.151","article-title":"The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia","volume":"23","author":"Mason","year":"2009","journal-title":"Leukemia"},{"key":"2021112216423015000_BCJ-2017-0080CC28","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"2021112216423015000_BCJ-2017-0080CC29","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","article-title":"Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models","volume":"14","author":"Shoemaker","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2021112216423015000_BCJ-2017-0080CC30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00280-009-1232-1","article-title":"The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo","volume":"66","author":"Ackler","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2021112216423015000_BCJ-2017-0080CC31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","article-title":"The Bcl-2\/Bcl-XL\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo","volume":"10","author":"Chen","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"2021112216423015000_BCJ-2017-0080CC32","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC33","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC34","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"2021112216423015000_BCJ-2017-0080CC35","first-page":"6565","article-title":"Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides","volume":"50","author":"Reed","year":"1990","journal-title":"Cancer Res."},{"key":"2021112216423015000_BCJ-2017-0080CC36","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O'Brien","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 family proteins are essential for platelet survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ."},{"key":"2021112216423015000_BCJ-2017-0080CC38","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"2021112216423015000_BCJ-2017-0080CC39","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"2021112216423015000_BCJ-2017-0080CC40","doi-asserted-by":"publisher","first-page":"e00178","DOI":"10.1002\/prp2.178","article-title":"Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax","volume":"3","author":"Ackler","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"2021112216423015000_BCJ-2017-0080CC41","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"2021112216423015000_BCJ-2017-0080CC43","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00277-016-2695-x","article-title":"Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia","volume":"95","author":"Seymour","year":"2016","journal-title":"Ann. Hematol."},{"key":"2021112216423015000_BCJ-2017-0080CC44","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC45","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.1200\/JCO.2016.34.15_suppl.7527","article-title":"Safety, efficacy and immune effects of venetoclax 400 mg daily in patients with relapsed chronic lymphocytic leukemia (CLL)","volume":"34","author":"Davids","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood.V126.23.715.715","article-title":"Preliminary results of a phase 2, open-label study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy","volume":"126","author":"Jones","year":"2015","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.488.488","article-title":"Venetoclax monotherapy for relapsed\/refractory multiple myeloma: safety and efficacy results from a phase I study","volume":"128","author":"Kumar","year":"2016","journal-title":"Blood."},{"key":"2021112216423015000_BCJ-2017-0080CC48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-hodgkin lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC49","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"2021112216423015000_BCJ-2017-0080CC50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-015-0460-8","article-title":"miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies","volume":"14","author":"Al-Harbi","year":"2015","journal-title":"Mol. Cancer"},{"key":"2021112216423015000_BCJ-2017-0080CC51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bph.13370","article-title":"Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding","volume":"173","author":"Song","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"2021112216423015000_BCJ-2017-0080CC52","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"2021112216423015000_BCJ-2017-0080CC53","doi-asserted-by":"publisher","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"key":"2021112216423015000_BCJ-2017-0080CC54","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"key":"2021112216423015000_BCJ-2017-0080CC55","doi-asserted-by":"publisher","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"2021112216423015000_BCJ-2017-0080CC56","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccr.2005.09.006","article-title":"The BAD protein integrates survival signaling by EGFR\/MAPK and PI3K\/Akt kinase pathways in PTEN-deficient tumor cells","volume":"8","author":"She","year":"2005","journal-title":"Cancer Cell"},{"key":"2021112216423015000_BCJ-2017-0080CC57","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"key":"2021112216423015000_BCJ-2017-0080CC58","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.3324\/haematol.2015.124560","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"key":"2021112216423015000_BCJ-2017-0080CC59","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC60","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC61","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC62","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1182\/blood-2017-01-761973","article-title":"Venetoclax and obinutuzumab in chronic lymphocytic leukemia","volume":"129","author":"Fischer","year":"2017","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC63","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood.V128.22.617.617","article-title":"Phase 2 study of venetoclax plus rituximab or randomized ven plus bendamustine+rituximab (BR) versus BR in patients with relapsed\/refractory follicular lymphoma: interim data","volume":"128","author":"Zinzani","year":"2016","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC64","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC65","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC66","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2021112216423015000_BCJ-2017-0080CC67","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br. J. Haematol."},{"key":"2021112216423015000_BCJ-2017-0080CC68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"2021112216423015000_BCJ-2017-0080CC69","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V128.22.639.639","article-title":"Phase 1b results of a phase 1b\/2 study of obinutuzmab, ibrutinib, and venetoclax in relapsed\/refractory chronic lymphocytic leukemia (CLL)","volume":"128","author":"Jones","year":"2016","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC70","doi-asserted-by":"publisher","first-page":"7548","DOI":"10.1200\/JCO.2016.34.15_suppl.7548","article-title":"The combination of ibrutinib and venetoclax (Abt-199) rapidly achieves complete remissions in patients with relapsed\/refractory mantle cell lymphoma: preliminary results of the phase II aim study","volume":"34","author":"Tam","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC71","doi-asserted-by":"publisher","first-page":"35202","DOI":"10.18632\/oncotarget.6051","article-title":"MCL-1-independent mechanisms of synergy between dual PI3K\/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"2021112216423015000_BCJ-2017-0080CC72","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2021112216423015000_BCJ-2017-0080CC73","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia"},{"key":"2021112216423015000_BCJ-2017-0080CC74","doi-asserted-by":"publisher","first-page":"16912","DOI":"10.18632\/oncotarget.4857","article-title":"Cyclin E\/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics","volume":"6","author":"Choudhary","year":"2015","journal-title":"Oncotarget"},{"key":"2021112216423015000_BCJ-2017-0080CC75","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/leu.2011.287","article-title":"MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex","volume":"26","author":"Konopleva","year":"2012","journal-title":"Leukemia"},{"key":"2021112216423015000_BCJ-2017-0080CC76","first-page":"6304","article-title":"Participation of P53 protein in the cellular response to DNA damage","volume":"51","author":"Kastan","year":"1991","journal-title":"Cancer Res."},{"key":"2021112216423015000_BCJ-2017-0080CC77","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90412-3","article-title":"Tumor suppressor p53 is a direct transcriptional activator of the human bax gene","volume":"80","author":"Miyashita","year":"1995","journal-title":"Cell"},{"key":"2021112216423015000_BCJ-2017-0080CC78","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","article-title":"Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis","volume":"288","author":"Oda","year":"2000","journal-title":"Science"},{"key":"2021112216423015000_BCJ-2017-0080CC79","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1097-2765(01)00213-1","article-title":"PUMA induces the rapid apoptosis of colorectal cancer cells","volume":"7","author":"Yu","year":"2001","journal-title":"Mol. Cell"},{"key":"2021112216423015000_BCJ-2017-0080CC80","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","article-title":"PUMA, a novel proapoptotic gene, is induced by p53","volume":"7","author":"Nakano","year":"2001","journal-title":"Mol. Cell"},{"key":"2021112216423015000_BCJ-2017-0080CC81","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/358080a0","article-title":"Amplification of a gene encoding a p53-associated protein in human sarcomas","volume":"358","author":"Oliner","year":"1992","journal-title":"Nature"},{"key":"2021112216423015000_BCJ-2017-0080CC82","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0968-0004(97)01119-5","article-title":"MDM2 \u2014 arbiter of p53's destruction","volume":"22","author":"Lane","year":"1997","journal-title":"Trends Biochem. Sci."},{"key":"2021112216423015000_BCJ-2017-0080CC83","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.4161\/cc.5.23.3520","article-title":"Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML","volume":"5","author":"Kojima","year":"2006","journal-title":"Cell Cycle"},{"key":"2021112216423015000_BCJ-2017-0080CC84","doi-asserted-by":"publisher","first-page":"e103015","DOI":"10.1371\/journal.pone.0103015","article-title":"Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737","volume":"9","author":"Gu","year":"2014","journal-title":"PLoS ONE"},{"key":"2021112216423015000_BCJ-2017-0080CC85","doi-asserted-by":"publisher","first-page":"e0139254","DOI":"10.1371\/journal.pone.0139254","article-title":"MDM2 inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation","volume":"10","author":"Borthakur","year":"2015","journal-title":"PLoS ONE"},{"key":"2021112216423015000_BCJ-2017-0080CC86","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-016-0280-3","article-title":"Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models","volume":"9","author":"Lehmann","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC87","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V126.23.673.673","article-title":"BCL-2 Inhibition by ABT-199 (venetoclax\/GDC-0199) and p53 activation by RG7388 (idasanutlin) reciprocally overcome leukemia apoptosis resistance to either strategy alone: efficacy and mechanisms","volume":"126","author":"Pan","year":"2015","journal-title":"Blood"},{"key":"2021112216423015000_BCJ-2017-0080CC88","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"key":"2021112216423015000_BCJ-2017-0080CC89","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"2021112216423015000_BCJ-2017-0080CC90","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/leu.2011.207","article-title":"CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors","volume":"26","author":"Negrotto","year":"2012","journal-title":"Leukemia"},{"key":"2021112216423015000_BCJ-2017-0080CC91","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1172\/JCI78789","article-title":"Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes","volume":"125","author":"Saunthararajah","year":"2015","journal-title":"J. Clin. Invest."},{"key":"2021112216423015000_BCJ-2017-0080CC92","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.1200\/JCO.2016.34.15_suppl.7009","article-title":"Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients \u226565 years ineligible for standard induction therapy","volume":"34","author":"Pollyea","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2021112216423015000_BCJ-2017-0080CC93","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","article-title":"BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members","volume":"15","author":"Hogg","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"2021112216423015000_BCJ-2017-0080CC94","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3109\/10428194.2014.981172","article-title":"ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in \u2018double hit\u2019 lymphoma cells","volume":"56","author":"Johnson-Farley","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"2021112216423015000_BCJ-2017-0080CC95","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/leu.2017.10","article-title":"Targeting BET family proteins improves the therapeutic efficacy of Bcl-2 inhibition in T-cell acute lymphoblastic leukemia","volume":"101","author":"Peirs","year":"2016","journal-title":"Haematologica"},{"key":"2021112216423015000_BCJ-2017-0080CC96","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1158\/0008-5472.CAN-16-1793","article-title":"Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies","volume":"77","author":"Bui","year":"2017","journal-title":"Cancer Res."},{"key":"2021112216423015000_BCJ-2017-0080CC97","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"2021112216423015000_BCJ-2017-0080CC98","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13543776.2017.1249848","article-title":"Mcl-1 inhibitors: a patent review","volume":"27","author":"Chen","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"2021112216423015000_BCJ-2017-0080CC99","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"2021112216423015000_BCJ-2017-0080CC100","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1021\/jm1001265","article-title":"BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma\/leukemia-2 (Bcl-2) family proteins","volume":"53","author":"Wei","year":"2010","journal-title":"J. Med. Chem."},{"key":"2021112216423015000_BCJ-2017-0080CC101","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1182\/blood-2007-09-113647","article-title":"Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)","volume":"111","author":"Kitada","year":"2008","journal-title":"Blood"}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/21\/3643\/690803\/bcj-2017-0080c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/21\/3643\/690803\/bcj-2017-0080c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:27:41Z","timestamp":1637623661000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/474\/21\/3643\/49518\/Therapeutics-targeting-Bcl-2-in-hematological"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":101,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20170080","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]}}}